T1	Participants 15 121	patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy
T2	Participants 414 566	inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL)
T3	Participants 576 614	A total of 188 poor prognosis patients
